Clinical Trial Update: A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) [Phase 3]

View source ↗

Summary

This document provides an update on a phase 3 clinical trial (SUCCESSOR-2) evaluating mezigdomide in combination with carfilzomib and dexamethasone versus carfi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Mezigdomide (mezigdomide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING